BrÃ-d M Ryan

List of Publications by Year
in descending order

73 papers	4,291 citations

218677

26 h-index	

110387

64 g-index

81 all docs	81 docs citations	81 times ranked	7745 citing authors

#	Article	IF	Citations
1	Accounting for <i>EGFR</i> Mutations in Epidemiologic Analyses of Non–Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 679-687.	2.5	1
2	Racial Disparities in Cigarette Smoking Behaviors and Differences Stratified by Metropolitan Area of Residence. International Journal of Environmental Research and Public Health, 2022, 19, 2910.	2.6	4
3	Automated next-generation profiling of genomic alterations in human cancers. Nature Communications, 2022, 13, .	12.8	8
4	Understanding the role of dopamine in cancer: past, present and future. Carcinogenesis, 2022, 43, 517-527.	2.8	24
5	LKB1 phosphorylation and deactivation in lung cancer by NNAL, a metabolite of tobacco-specific carcinogen, in an isomer-dependent manner. Oncogene, 2022, 41, 4042-4054.	5.9	8
6	The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients. Lung Cancer, 2021, 152, 58-65.	2.0	22
7	A reply to â€œLung cancer outcomes: Are BMI and race clinically relevant?â€• Lung Cancer, 2021, 154, 225-226.	2.0	0
8	In Response: Using Propensity Score Matching to Balance the Baseline Characteristics. Journal of Thoracic Oncology, 2021, 16, e46.	1.1	1
9	JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance. Carcinogenesis, 2021, 42, 1411-1419.	2.8	30
10	A comprehensive map of alternative polyadenylation in African American and European American lung cancer patients. Nature Communications, 2021, 12, 5605.	12.8	9
11	A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing. Nature Communications, 2021, 12, 6512.	12.8	24
12	Cytokine Storms in Cancer and COVID-19. Cancer Cell, 2020, 38, 598-601.	16.8	66
13	Whole-Exome Profiling of NSCLC Among African Americans. Journal of Thoracic Oncology, 2020, 15, 1880-1892.	1.1	19
14	Higher prevalence of homologous recombination deficiency in tumors from African Americans versus European Americans. Nature Cancer, 2020, 1, 112-121.	13.2	30
15	Lung Cancer Risk in Never-Smokers of European Descent is Associated With Genetic Variation in the 5p15.33 TERT-CLPTM1Ll Region. Journal of Thoracic Oncology, 2019, 14, 1360-1369.	1.1	27
16	Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. Journal of Thoracic Oncology, 2019, 14, 1594-1607.	1.1	81
17	Relationship between West African ancestry with lung cancer risk and survival in African Americans. Cancer Causes and Control, 2019, 30, 1259-1268.	1.8	11
18	Circulating Inflammation Proteins Associated With Lung Cancer in African Americans. Journal of Thoracic Oncology, 2019, 14, 1192-1203.	1.1	20

#	ARTICLE	IF	CITATIONS
19	Prenatal smoke exposure, DNA methylation and a link between DRD1 and lung cancer. International Journal of Epidemiology, 2019, 48, 1377-1378.	1.9	2
20	Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans. Nature Communications, 2019, 10, 5735.	12.8	22
21	Relationship between Circulating Inflammation Proteins and Lung Cancer Diagnosis in the National Lung Screening Trial. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 110-118.	2.5	22
22	Histologic Lung Cancer Incidence Rates and Trends Vary by Race/Ethnicity and Residential County. Journal of Thoracic Oncology, 2018, 13, 497-509.	1.1	49
23	Lung cancer health disparities. Carcinogenesis, 2018, 39, 741-751.	2.8	66
24	Stressing the need to overcome EGFR tyrosine kinase inhibitor resistance. Translational Lung Cancer Research, 2018, 7, S123-S126.	2.8	1
25	Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach. Translational Lung Cancer Research, 2018, 7, S265-S269.	2.8	1
26	IFNL4-Î"G is associated with prostate cancer among men at increased risk of sexually transmitted infections. Communications Biology, 2018, 1, 191.	4.4	28
27	Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer. journal of applied laboratory medicine, The, 2018, 3, 166-177.	1.3	6
28	Racial and Ethnic Differences in the Relationship between Aspirin Use and Nonâ€"Small Cell Lung Cancer Risk and Survival. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1518-1526.	2.5	10
29	Inverse association of vitamin D$_3$ levels with lung cancer mediated by genetic variation. Cancer Medicine, 2018, 7, 2764-2775.	2.8	14
30	Interaction between the microbiome and TP53 in human lung cancer. Genome Biology, 2018, 19, 123.	8.8	247
31	Relationship between anti-depressant use and lung cancer survival. Cancer Treatment and Research Communications, 2017, 10, 33-39.	1.7	30
32	Assessment of Variability in the SOMAscan Assay. Scientific Reports, 2017, 7, 14248.	3.3	263
33	microRNAs in Cancer Susceptibility. Advances in Cancer Research, 2017, 135, 151-171.	5.0	36
34	Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Differences in NSCLC from African Americans and European Americans. Clinical Cancer Research, 2017, 23, 7412-7425.	7.0	83
35	A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts. Journal of Thoracic Oncology, 2017, 12, 65-76.	1.1	26
36	Identification of serum inflammatory markers as classifiers of lung cancer mortality for stage I adenocarcinoma. Oncotarget, 2017, 8, 40946-40957.	1.8	26

#	ARTICLE	IF	CITATIONS
37	Abstract 4925: Microbiome-TP53 gene interaction in human lung cancer. , 2017, , .		0
38	Differential eligibility of African American and European American lung cancer cases using LDCT screening guidelines. BMJ Open Respiratory Research, 2016, 3, e000166.	3.0	24
39	MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer. Scientific Reports, 2016, 6, 33153.	3.3	8
40	Genome-wide association study confirms lung cancer susceptibility loci on chromosomes 5p15 and 15q25 in an African-American population. Lung Cancer, 2016, 98, 33-42.	2.0	49
41	Gene expression classifier for prognosis of early-stage squamous cell carcinoma of the lung. Journal of Thoracic Oncology, 2016, 11, S38-S39.	1.1	1
42	A functional SNP in MRPL43 modulates lung cancer susceptibility and survival through alternative splicing of its isoforms. Journal of Thoracic Oncology, 2016, 11, S39-S40.	1.1	1
43	Differential Serum Cytokine Levels and Risk of Lung Cancer Between African and European Americans. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 488-497.	2.5	32
44	KRT81 miR-SNP rs3660 is associated with risk and survival of NSCLC. Annals of Oncology, 2016, 27, 360-361.	1.2	8
45	The hallmarks of premalignant conditions: a molecular basis for cancer prevention. Seminars in Oncology, 2016, 43, 22-35.	2.2	27
46	Associations between the *MDM2* promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate. Oncotarget, 2016, 7, 28637-28646.	1.8	22
47	Chapter 4. The Role of Catecholamines in Stem Cell Mobilisation. Issues in Toxicology, 2016, , 64-93.	0.1	0
48	Identification of a Functional SNP in the 3â€²UTR of CXCR2 That Is Associated with Reduced Risk of Lung Cancer. Cancer Research, 2015, 75, 566-575.	0.9	53
49	Abstract LB-295: Analysis of miR-21 isomiRs in lung cancer. , 2015, , .		0
50	Germline variation in *NCF4*, an innate immunity gene, is associated with an increased risk of colorectal cancer. International Journal of Cancer, 2014, 134, 1399-1407.	5.1	70
51	Hemeâ€related gene expression signatures of meat intakes in lung cancer tissues. Molecular Carcinogenesis, 2014, 53, 548-556.	2.7	13
52	A *DRD1* Polymorphism Predisposes to Lung Cancer among Those Exposed to Secondhand Smoke during Childhood. Cancer Prevention Research, 2014, 7, 1210-1218.	1.5	25
53	A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Journal of Thoracic Oncology, 2014, 9, 1494-1503.	1.1	45
54	Evidence that the Lung Adenocarcinoma EML4-ALK Fusion Gene Is not Caused by Exposure to Secondhand Tobacco Smoke During Childhood. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1432-1434.	2.5	4

#	ARTICLE	IF	CITATIONS
55	An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer. Cancer Epidemiology, 2014, 38, 583-590.	1.9	26
56	Abstract 2156: Childhood exposure to secondhand smoke, nicotine dependence, and DRD1 are associated with lung cancer risk. , 2014, , .		0
57	Asymmetric segregation of template DNA strands in basal-like human breast cancer cell lines. Molecular Cancer, 2013, 12, 139.	19.2	15
58	Innate immunity gene polymorphisms and the risk of colorectal neoplasia. Carcinogenesis, 2013, 34, 2512-2520.	2.8	11
59	Abstract 4581: Interaction between DRD1 and childhood exposure to environmental tobacco smoke modulates lung cancer risk in smokers and never smokers.. , 2013, , .		1
60	3â€²-UTR and Functional Secretor Haplotypes in Mannose-Binding Lectin 2 Are Associated with Increased Colon Cancer Risk in African Americans. Cancer Research, 2012, 72, 1467-1477.	0.9	68
61	KRAS-LCS6 Genotype as a Prognostic Marker in Early-Stage CRCâ€"Letter. Clinical Cancer Research, 2012, 18, 3487-3488.	7.0	27
62	rs4919510 in hsa-mir-608 Is Associated with Outcome but Not Risk of Colorectal Cancer. PLoS ONE, 2012, 7, e36306.	2.5	85
63	MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer. International Journal of Cancer, 2012, 131, 2710-2716.	5.1	20
64	Genetic variation in microRNA networks: the implications for cancer research. Nature Reviews Cancer, 2010, 10, 389-402.	28.4	1,184
65	Microenvironmental modulation of asymmetric cell division in human lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2195-2200.	7.1	122
66	Survivin: A new target for anti-cancer therapy. Cancer Treatment Reviews, 2009, 35, 553-562.	7.7	346
67	ADAM-17 predicts adverse outcome in patients with breast cancer. Annals of Oncology, 2008, 19, 1075-1081.	1.2	75
68	ADAM-17 Expression in Breast Cancer Correlates with Variables of Tumor Progression. Clinical Cancer Research, 2007, 13, 2335-2343.	7.0	108
69	Survivin: A promising tumor biomarker. Cancer Letters, 2007, 249, 49-60.	7.2	229
70	Lipophilin B: A gene preferentially expressed in breast tissue and upregulated in breast cancer. International Journal of Cancer, 2006, 120, 1087-1092.	5.1	13
71	Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Annals of Oncology, 2006, 17, 597-604.	1.2	128
72	Expression of survivin and its splice variants survivin-2B and survivin-Î"Ex3 in breast cancer. British Journal of Cancer, 2005, 92, 120-124.	6.4	89

#	Article	IF	Citations
73	Mammaglobin a in breast cancer: Existence of multiple molecular forms. International Journal of Cancer, 2005, 114, 623-627.	5.1	15